PDRN CarePDRN for Wound Healing in Diabetic Models: A Preclinical Study (2008)
Dr. Sarah Chen
PhD, Molecular Biology
Key Findings
PDRN-treated diabetic mice showed significantly faster wound closure compared to saline-treated controls, with complete healing achieved 5-7 days earlier [1].
VEGF expression was markedly increased in PDRN-treated wounds, restoring angiogenic capacity to near-normal levels despite the diabetic impairment [1,2].
The wound-healing effects of PDRN were blocked by the selective A2A receptor antagonist DMPX, confirming that the therapeutic mechanism is mediated through adenosine A2A receptor activation [1].
Key Findings
- PDRN-treated diabetic mice showed significantly faster wound closure compared to saline-treated controls, with complete healing achieved 5-7 days earlier [1].
- VEGF expression was markedly increased in PDRN-treated wounds, restoring angiogenic capacity to near-normal levels despite the diabetic impairment [1][2].
- The wound-healing effects of PDRN were blocked by the selective A2A receptor antagonist DMPX, confirming that the therapeutic mechanism is mediated through adenosine A2A receptor activation [1].
Abstract
This preclinical study by Galeano et al. investigated the wound-healing properties of PDRN in genetically diabetic (db/db) mice, a well-established model of impaired wound healing [1]. Diabetic wounds are characterized by reduced growth factor expression, impaired angiogenesis, and persistent inflammation — closely mirroring the pathology of diabetic foot ulcers in humans [1][5]. PDRN was administered via local injection at the wound site, and healing was assessed by wound area reduction, histological analysis, and molecular markers [1].
Methods
Full-thickness excisional wounds (1 cm diameter) were created on the dorsum of db/db diabetic mice and wild-type controls [1]. Animals received either PDRN (8 mg/kg, local injection every other day) or saline vehicle for the duration of the study [1]. A subset of PDRN-treated animals also received DMPX (3,7-dimethyl-1-propargylxanthine), a selective A2A receptor antagonist, to test the receptor-dependency of the observed effects [1].
Primary endpoints included wound area (planimetric measurement), time to complete closure, VEGF protein expression (Western blot), capillary density (histological quantification), and inflammatory markers [1].
Results
PDRN-treated diabetic mice demonstrated significantly accelerated wound healing compared to saline-treated diabetic controls [1]. Wound area at day 14 was reduced by approximately 45% in the PDRN group versus controls [1]. Complete wound closure occurred by day 21 in PDRN-treated animals, compared to day 28 in controls [1].
Mechanistically, PDRN treatment produced [1][2]:
- VEGF upregulation — PDRN-treated wounds showed a 3.5-fold increase in VEGF protein expression versus diabetic controls, restoring levels to near-wild-type values [1]
- Increased capillary density — Histological analysis revealed significantly more capillaries per high-power field in PDRN-treated wounds [1]
- Reduced inflammatory infiltrate — PDRN-treated wounds showed less persistent neutrophilic infiltration and earlier transition to the proliferative phase [1][4]
Critically, co-administration of the A2A antagonist DMPX abolished all PDRN-mediated improvements in wound healing, VEGF expression, and angiogenesis [1]. This pharmacological reversal provided strong evidence that PDRN's therapeutic effects are specifically mediated through adenosine A2A receptor activation [1][2].
Significance
This study is considered a landmark in PDRN research for several reasons [2][3]:
- Mechanism confirmation — It provided the first clear demonstration that PDRN's wound-healing effects are specifically A2A receptor-dependent, establishing the mechanistic foundation for all subsequent PDRN research [1][2]
- Impaired healing model — By demonstrating efficacy in a diabetic model with inherently compromised healing, the study showed that PDRN can overcome pathological barriers to repair, not just accelerate normal healing [1][3]
- Clinical translation — The findings directly supported the development of PDRN for clinical wound healing and subsequently for aesthetic applications where tissue regeneration is the therapeutic goal [2][3]
Conclusion
This study established that PDRN stimulates angiogenesis and accelerates wound closure in diabetic models through A2A receptor activation [1]. The restoration of VEGF expression in growth factor-deficient diabetic tissue provided a compelling rationale for PDRN's use in any condition where impaired tissue repair or regeneration is present — including the photoaged and chronically inflamed skin targeted by aesthetic PDRN treatments [2][3].
References
- [1]Galeano M, Bitto A, Altavilla D, Minutoli L, Polito F, Calò M, Lo Cascio P, Stagno d'Alcontres F, Squadrito F. Polydeoxyribonucleotide stimulates angiogenesis and wound healing in the genetically diabetic mouse. Wound Repair and Regeneration. 2008;16(2):208-217. doi:10.1111/j.1524-475X.2008.00361.x
- [2]Squadrito F, Bitto A, Irrera N, Pizzino G, Pallio G, Minutoli L, Altavilla D. Pharmacological Activity and Clinical Use of PDRN. Current Pharmaceutical Design. 2017;23(27):3948-3957. doi:10.2174/1381612823666170516153716
- [3]Veronesi F, Dallari D, Sabbioni G, Carubbi C, Martini L, Fini M. Polydeoxyribonucleotides (PDRNs): From Physical Chemistry to Biological Activities and Clinical Applications. International Journal of Molecular Sciences. 2017;18(9):1927. doi:10.3390/ijms18091927
- [4]Bitto A, Polito F, Irrera N, et al.. Polydeoxyribonucleotide reduces cytokine production and the severity of collagen-induced arthritis by stimulation of adenosine A2A receptor. Arthritis Research & Therapy. 2011;13(1):R28. doi:10.1186/ar3254
- [5]Barrientos S, Stojadinovic O, Golinko MS, Brem H, Tomic-Canic M. Growth factors and cytokines in wound healing. Wound Repair and Regeneration. 2008;16(5):585-601. doi:10.1111/j.1524-475X.2008.00410.x